摘要
目的探究聚乙二醇干扰素α-2a注射液联合利巴韦林治疗慢性丙肝的临床效果。方法选择2016年6月~2017年7月期间我院收治的50例慢性丙肝患者,依据入院先后顺序平均分为观察组和对照组,每组25例。对照组治疗药物选择利巴韦林,观察组治疗药物为聚乙二醇干扰素α-2a注射液联合利巴韦林,对比两组患者的临床治疗效果。结果①观察组患者EVR、ETVR和SVR比例均高于对照组患者,NR比例低于对照组患者,组间差异有统计学意义(P<0.05);②两组患者治疗前AST和ALT水平比较,差异无统计学意义(P>0.05);两组患者治疗后AST和ALT水平比较,差异有统计学意义(P<0.05)。结论慢性丙肝患者采用聚乙二醇干扰素α-2a注射液联合利巴韦林进行治疗疗效确切,安全性良好,可将其进行临床推广。
Objective To investigate the clinical effect of peginterferon α-2a injection combined with ribavirin in the treatment of chronic hepatitis C. Methods Fifty patients with chronic hepatitis C admitted in our hospital from June 2016 to July 2017 were enrolled. The 50 patients were divided into observation group and control group according to the order of admission, with 25 cases in each group. The control group was treated with ribavirin, and the treatment group was peginterferon α-2a injection combined with ribavirin. The clinical effects of the two groups were compared. Results ①The proportions of EVR, ETVR and SVR in the observation group were higher than those in the control group. The NR ratio was lower than that in the control group, the differences were statistically significant between the two groups(P<0.05).②There was no significant difference in the levels of AST and ALT between the two groups before treatment(P>0.05). The levels of AST and ALT were significantly different between the two groups after treatment, and the differences were statistically significant(P<0.05). Conclusion Peginterferon α-2a injection combined with ribavirin in the treatment of chronic hepatitis C patients is effective and safe, and can be clinically promoted.
作者
徐定娟
XU Dingjuan(Department of Infectious Diseases, Zaozhuang Mining Group Tengnan Hospital, Zaozhuang 277606, China)
出处
《中国现代医生》
2019年第6期87-89,共3页
China Modern Doctor